Company intelligence / Profile preview
Aucta Pharmaceuticals, Inc.
Piscataway, New Jersey, United Statesauctapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aucta successfully launched its first branded product, Motpoly XR (lacosamide), in the epilepsy space in mid-February 2024. The FDA approved Motpoly XR for partial onset seizures in May 2023, and it received a new indication for Primary Generalized Tonic-Clonic Seizures (Adjunctive Treatment) in June 2024[3][7].
- Therapeutic areas
- OphthalmologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecule drugsMolecular glue
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Aucta Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aucta Pharmaceuticals, Inc..